改善慢性精神分裂症患者认知障碍的新型数字干预:一项随机临床试验
Lingzi Xu1, Wenjing Yang1, Ruoxin Fan2
1Infinite Brain Technologies, Beijing, China.
Schizophrenia research
|November 6, 2024
概括
一种新的数字治疗方法IBT-SC02显著改善了稳定的精神分裂症患者的认知功能. 这种数字干预显示出治疗精神分裂症认知障碍的前景,提供了一种新的治疗选择.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 数字治疗学数字治疗学
背景情况:
- 认知障碍是精神分裂症的一个重大挑战.
- 对精神分裂症认知缺陷的可访问,独立的数字治疗方法有需要.
- IBT-SC02是一种新的数字治疗,旨在解决认知障碍.
研究的目的:
- 评估IBT-SC02在改善稳定精神分裂症患者的认知表现方面的疗效.
- 评估IBT-SC02作为治疗精神分裂症认知障碍的可接受性.
- 确定IBT-SC02是否可以作为对获得专业护理的机会有限的个体的可行治疗选择.
主要方法:
- 一个随机的平行组试验与80名稳定的精神分裂症患者 (年龄18-50岁) 进行.
- 参与者被随机分配到IBT-SC02干预组或等待名单对照组.
- 认知表现使用 MATRICS 共识认知电池 (MCCB) 复合得分作为主要结果进行评估.
主要成果:
- 与对照组相比,IBT-SC02组在MCCB复合得分上显示出显著的改善.
- 后期分析表明,MCCB的四个领域有所改善:处理速度,口头学习,视觉学习和推理/解决问题的能力.
- 很低的退学率 (5%) 和没有报告的不良事件表明良好的耐受性.
结论:
- 在稳定的精神分裂症患者中,IBT-SC02在提高认知表现方面表现出有效性.
- 由于IBT-SC02的全自动化特性,使其成为一种潜在的可扩展的治疗选择,特别是对于那些无法获得训练有素的专业人员的人来说.
- IBT-SC02代表了一种有前途的数字治疗方法,用于治疗精神分裂症患者的认知障碍.
更多相关视频
相关概念视频
Negative and Cognitive Symptoms of Schizophrenia
44
Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
44
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
98
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
98


